Efficacy studies on a canarypox-rabies recombinant virus.
Recombinant avipox viruses have been developed expressing the rabies glycoprotein gene. A fowlpox-rabies recombinant has previously been shown to be protective against live rabies virus challenge in a number of non-avian species. This report describes the development of a canarypox-rabies recombinant. A comparison is made of the protective efficacy of this recombinant with other pox-rabies recombinants.
Taylor
J
J
Virogenetics Corporation, Troy, New York 12180.
Trimarchi
C
C
Weinberg
R
R
Languet
B
B
Guillemin
F
F
Desmettre
P
P
Paoletti
E
E
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002415:Cats; D004274:DNA, Recombinant; D004285:Dogs; D051379:Mice; D011212:Poxviridae / Q000235:genetics* / Q000276:immunology; D011818:Rabies / Q000517:prevention & control*; D011820:Rabies virus / Q000235:genetics / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology
D000914:Antibodies, Viral; D004274:DNA, Recombinant; D014614:Vaccines, Synthetic; D014765:Viral Vaccines